malaysia onclogy
   
 
malaysiaoncology.org | Malaysian Oncological Society
home home home home
    search
Terminology
Misconceptions
Diagnosis
Treatments
Common Cancers
Informed Decision
Featured Expert
Palliative Care
Specialist Centres
Upcoming Events
Frequently Asked Questions
Web Resources
In the News & Newsletters
Supportive Info
Clinical Trials
Photo Gallery
Cancer Survivorship
President's Message
Living with Cancer
Toolbox
Join as a Member of MOS
MOS Committee
Announcements & Updates
Home
Feedback
   
 

Main sponsors:
AstraZeneca Sdn Bhd
Novartis Corporation (Malaysia) Sdn. Bhd
Roche (Malaysia) Sdn. Bhd.
Sanofi-Aventis Malaysia Sdn Bhd
GlaxoSmithKline Pharmaceutical Sdn Bhd
Pfizer Malaysia Sdn Bhd
  arrow Featured Expert

 

Professor Dr. Mark Pegram

8 July 2008


Confirming HER-2 positivity

The positive diagnosis of HER-2 breast cancer should be confirmed by a central reference laboratory due to the high number of falsepositives in community testing, says a US researcher.

Professor Dr. Mark Pegram further advocated the use of trastuzumab in patients identified with HER- 2 amplifiable early stage breast cancer, preferably confirmed by a central reference laboratory.

He also provided a Southern California perspective about the treatment regimens of trastuzumab, which he said should be given at six mg/kg every three weeks for a year. This, he explained, is based on current dosing data of the drug. Trastuzumab regimens
can also be used with chemotherapy in patients who are candidates for combination therapy. Radiation can be used safely with trastuzumab,based on current data.

He also said endocrine receptor therapy has demonstrated equal benefits in ERpositive and ER-negativepatients. - AW

----------------------------------------------------

Dr. Mark Pegram is an Associate Professor of Medicine in the Division of Hematology/Oncology at the UCLA School of Medicine, and is currently Director of the Womenís Cancer Program at the UCLA/Jonsson Comprehensive Cancer Center. Dr. Pegram took his medical training at the University of North Carolina, Chapel Hill and attended medical internship and residency at the University of Texas Southwestern Medical School in Dallas,TX Parkland Memorial Hospital before moving to UCLA for fellowship training in Hematology/Oncology. Dr. Pegram conducted his research fellowship in Dr. Dennis Slamonís laboratory at UCLA before joining the UCLA faculty in 1993. Dr. Pegram has a number of honors and awards to his credit including the Revlon/UCLA Fellowship, the UCLA Clinical Cancer Research Career Development Award, and the Basic Science Award from the Society of Gynecologic Oncology. Dr. Pegramís expertise is in the development of targeted therapeutics in solid tumor oncology. Dr. Pegram has grant support for his work in the area of targeting growth factor receptors and angiogenesis in breast cancer. Dr. Pegram has numerous publications to his credit including authorships or co-authorships in the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Biochemistry, Oncogene, Journal of Organic Chemistry, Clinical Cancer Research, Biochemical Pharmacology, Cancer Gene Therapy, and Breast Cancer Research and Treatment.
 


  printer Printer-friendly version


  back   Go Back




HOPE handbook A Resource Guidebook for Newly Diagnosed Cancer Patients
Ľ HOPE Handbook
 

HOPE handbook 2 A Guide for Cancer Caregivers
Ľ HOPE Handbook 2
 
terms of use | sponsors | credits

Copyright © malaysiaoncology.org 2004 - 2012   All rights reserved
designed & maintained: mobition